In vitro modulation of cisplatin cytotoxicity by sparsomycin inhibition of protein synthesis
- PMID: 3470545
In vitro modulation of cisplatin cytotoxicity by sparsomycin inhibition of protein synthesis
Abstract
Inhibition of protein synthesis can alter cellular responsiveness to the classical anticancer drugs. The in vitro response of Chinese hamster ovary (CHO) cells to cisplatin with or without sparsomycin (Sm) was studied with the use of [3H]leucine and [methyl-3H]thymidine incorporation and clonogenic assay. Pretreatment of exponentially growing CHO cells with 1 microgram Sm/ml for 3 or 5 hours decreased [3H]leucine incorporation by 20% and resulted in significant resistance to cisplatin (P = .005). Sm in a concentration of 10 micrograms/ml reduced [3H]leucine and [methyl-3H]thymidine incorporation after 3 hours by 92 and 84%, respectively, and resulted in potentiation of the cisplatin cytotoxicity (P = .004). This effect was the same in the case of nonproliferating cells (P = .005), while protection due to Sm (1 microgram/ml) was seen only during cell proliferation. Simultaneous incubation and postincubation with Sm proved to have much less or no potentiating effect on cisplatin. The mechanisms of both protection and potentiation are still not clear, but our data indicate that Sm is a promising drug for further studies on the modulation of the cancer cell response to classical anticancer drugs.
Similar articles
-
Modulation of the in vitro cytotoxicity of seven anticancer drugs by protein synthesis inhibition using sparsomycin.Anticancer Res. 1989 Nov-Dec;9(6):1835-40. Anticancer Res. 1989. PMID: 2483308
-
Potentiation of DNA-reactive antineoplastic agents and protection against S-phase-specific agents by anguidine in Chinese hamster ovary cells.Cancer Res. 1983 Jul;43(7):3070-3. Cancer Res. 1983. PMID: 6189590
-
The development of sparsomycin as an anti-tumour drug.Anticancer Drug Des. 1988 Mar;2(4):333-7. Anticancer Drug Des. 1988. PMID: 3365303
-
Protection of Chinese hamster ovary cells from hyperthermic killing by cycloheximide or puromycin.Radiat Res. 1986 Apr;106(1):98-110. Radiat Res. 1986. PMID: 3961108
-
Chemical and biological aspects of sparsomycin, an antibiotic from Streptomyces.Prog Med Chem. 1986;23:219-68. doi: 10.1016/s0079-6468(08)70344-8. Prog Med Chem. 1986. PMID: 3310108 Review. No abstract available.
Cited by
-
Altering chemosensitivity by modulating translation elongation.PLoS One. 2009;4(5):e5428. doi: 10.1371/journal.pone.0005428. Epub 2009 May 1. PLoS One. 2009. PMID: 19412536 Free PMC article.
-
In vivo antitumor activity of sparsomycin and its analogues in eight murine tumor models.Invest New Drugs. 1988 Dec;6(4):285-92. doi: 10.1007/BF00173646. Invest New Drugs. 1988. PMID: 3229941
-
Correlation of the in vitro cytotoxicity of ethyldeshydroxysparsomycin and cisplatin with the in vivo antitumour activity in murine L1210 leukaemia and two resistant L1210 subclones.Cancer Chemother Pharmacol. 1993;31(4):289-94. doi: 10.1007/BF00685673. Cancer Chemother Pharmacol. 1993. PMID: 8422692
-
Pharmacokinetics and toxicology of sparsomycin in beagle dogs.Cancer Chemother Pharmacol. 1987;20(2):115-24. doi: 10.1007/BF00253964. Cancer Chemother Pharmacol. 1987. PMID: 3664930
-
Preclinical antitumor activity of ethyldeshydroxysparsomycin in combination with cisplatin.Invest New Drugs. 1995;13(1):23-32. doi: 10.1007/BF02614216. Invest New Drugs. 1995. PMID: 7499104